新辅助化疗在转移性髓母细胞瘤中的作用:92例儿童的比较研究
该回顾性研究比较了2002至2015年在Gustave Roussy治疗的92例转移性髓母细胞瘤患儿,54例诊断时手术(A组),38例接受卡铂和依托泊苷为基础的新辅助化疗后延迟手术(B组)。B组完全切除率显著高于A组(93.3% vs 57.4%,P=0.0013),术后并发症、化疗副作用和局部进展未增加,5年无进展生存和总生存两组相当,智力结局B组 tended to be better(平均预测智商值在整个随访期间高6分)。
要点
- 术前化疗提高完全肿瘤切除率(93.3% vs 57.4%,P=0.0013)。
- 延迟手术未增加毒性或疾病进展风险。
- 术前化疗可能对神经心理结局有积极影响。
核心结论
- 术前化疗是转移性髓母细胞瘤安全有效的策略,提高完全肿瘤切除率并可能改善神经心理结局而不危及生存。
研究设计与样本
- 回顾性比较92例2002至2015年在Gustave Roussy治疗的转移性髓母细胞瘤患者,A组诊断时手术(n=54),B组卡铂和依托泊苷为基础新辅助化疗后延迟手术(n=38),两组治疗策略相似。
主要发现
- B组完全肿瘤切除率显著高于A组(93.3% vs 57.4%,P=0.0013)。
- B组术后并发症、化疗相关副作用和局部进展未增加。
- 新辅助化疗使所有患者原发肿瘤缩小,但4/38例患者出现远处进展。
- 19对匹配肿瘤(化疗前后)的组织学复查显示增殖减少,组织学诊断可行且准确。
- 5年无进展生存和总生存两组相当;纵向神经心理数据显示B组智力结局 tended to be better(平均预测智商值在整个随访期间高6分)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous pilot studies have shown the feasibility of preoperative chemotherapy in patients with medulloblastoma, but benefits and risks compared with initial surgery have not been assessed. METHODS: Two therapeutic strategies were retrospectively compared in 92 patients with metastatic medulloblastoma treated at Gustave Roussy between 2002 and 2015: surgery at diagnosis (n = 54, group A) and surgery delayed after carboplatin and etoposide-based neoadjuvant therapy (n = 38, group B). Treatment strategies were similar in both groups. RESULTS: The rate of complete tumor excision was significantly higher in group B than in group A (93.3% vs 57.4%, P = 0.0013). Postoperative complications, chemotherapy-associated side effects, and local progressions were not increased in group B. Neoadjuvant chemotherapy led to a decrease in the primary tumor size in all patients; meanwhile 4/38 patients experienced a distant progression. The histological review of 19 matched tumor pairs (before and after chemotherapy) showed that proliferation was reduced and histological diagnosis feasible and accurate even after neoadjuvant chemotherapy. The 5-year progression-free and overall survival rates were comparable between groups. Comparison of the longitudinal neuropsychological data showed that intellectual outcome tended to be better in group B (the mean predicted intellectual quotient value was 6 points higher throughout the follow-up). CONCLUSION: Preoperative chemotherapy is a safe and efficient strategy for metastatic medulloblastoma. It increases the rate of complete tumor excision and may improve the neuropsychological outcome without jeopardizing survival. KEY POINTS: 1. Preoperative chemotherapy increases the rate of complete tumor removal.2. No additional risk (toxic or disease progression) is linked to the delayed surgery.3. Preoperative chemotherapy could have a positive impact on the neuropsychological outcome of patients.
引用
- Guerrini-Rousseau L, Abbas R, Huybrechts S, et al. Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children. Neuro Oncol. 2020. PMID: 32267940. doi:10.1093/neuonc/noaa083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。